litlas
ログインアカウント作成

David M. Goldenberg

1966–2024 年に発表

161
論文数
25,955
被引用数
103
h 指数
160
i10 指数

被引用数

David M. Goldenberg の年別被引用数1972 年: 被引用 1 件1973 年: 被引用 1 件1974 年: 被引用 4 件1975 年: 被引用 1 件1976 年: 被引用 2 件1977 年: 被引用 1 件1978 年: 被引用 6 件1979 年: 被引用 4 件1980 年: 被引用 14 件1981 年: 被引用 16 件1982 年: 被引用 19 件1983 年: 被引用 24 件1984 年: 被引用 23 件1985 年: 被引用 18 件1986 年: 被引用 11 件1987 年: 被引用 9 件1988 年: 被引用 1 件1989 年: 被引用 10 件1990 年: 被引用 7 件1991 年: 被引用 11 件1992 年: 被引用 5 件1993 年: 被引用 16 件1994 年: 被引用 14 件1995 年: 被引用 18 件1996 年: 被引用 18 件1997 年: 被引用 17 件1998 年: 被引用 24 件1999 年: 被引用 43 件2000 年: 被引用 34 件2001 年: 被引用 46 件2002 年: 被引用 64 件2003 年: 被引用 83 件2004 年: 被引用 72 件2005 年: 被引用 144 件2006 年: 被引用 120 件2007 年: 被引用 189 件2008 年: 被引用 156 件2009 年: 被引用 130 件2010 年: 被引用 197 件2011 年: 被引用 180 件2012 年: 被引用 166 件2013 年: 被引用 184 件2014 年: 被引用 102 件2015 年: 被引用 201 件2016 年: 被引用 119 件2017 年: 被引用 157 件2018 年: 被引用 114 件2019 年: 被引用 551 件2020 年: 被引用 605 件2021 年: 被引用 798 件2022 年: 被引用 784 件2023 年: 被引用 721 件2024 年: 被引用 1,108 件2025 年: 被引用 537 件2026 年: 被引用 7 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,927 件、この内訳の 29.4%中国: 引用元論文 684 件、この内訳の 10.5%ドイツ: 引用元論文 415 件、この内訳の 6.3%イタリア: 引用元論文 337 件、この内訳の 5.2%イギリス: 引用元論文 325 件、この内訳の 5%フランス: 引用元論文 298 件、この内訳の 4.6%オランダ: 引用元論文 198 件、この内訳の 3%カナダ: 引用元論文 184 件、この内訳の 2.8%スペイン: 引用元論文 168 件、この内訳の 2.6%日本: 引用元論文 158 件、この内訳の 2.4%スイス: 引用元論文 153 件、この内訳の 2.3%オーストラリア: 引用元論文 139 件、この内訳の 2.1%
0%29.4%その他 23.8%

機関

分野

  • Medicine72%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Immunology and Microbiology5.2%
  • Engineering3.1%
  • Materials Science1.7%
  • Chemistry1.2%
  • その他3%

トピック

  • Monoclonal and Polyclonal Antibodies Research9.5%
  • HER2/EGFR in Cancer Research7.3%
  • Radiopharmaceutical Chemistry and Applications5.6%
  • CAR-T cell therapy research3.5%
  • Advanced Breast Cancer Therapies2.5%
  • Cancer Immunotherapy and Biomarkers2.2%
  • その他69.4%

共著者

全論文

検索で開く
  1. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    著者: Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo - New England Journal of Medicine 2021 被引用: 1,543

  2. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

    著者: Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky - New England Journal of Medicine 2019 被引用: 850

  3. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

    著者: Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, Jordan Berlin, Linda T. Vahdat, Gregory A. Masters, R Moroose, Alessandro D. Santin, Kevin Kalinsky, Vincent J. Picozzi, Joyce O’Shaughnessy, Jhanelle E. Gray, Takefumi Komiya, Joshua M. Lang, Jenny C. Chang, Alexander Starodub, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, William A. Wegener, Trishna Goswami, Allyson J. Ocean - Annals of Oncology 2021 被引用: 375

  4. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

    著者: David M. Goldenberg, Thomas M. Cardillo, Serengulam V. Govindan, Edmund A. Rossi, Robert M. Sharkey - Oncotarget 2015 被引用: 474

  5. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    著者: Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz - Annals of Oncology 2021 被引用: 299

  6. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

    著者: David M. Goldenberg, Rhona Stein, Robert M. Sharkey - Oncotarget 2018 被引用: 312

  7. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

    著者: Alexander Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Linda T. Vahdat, Sajeve Thomas, Serengulam V. Govindan, Pius Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg - Clinical Cancer Research 2015 被引用: 344

  8. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

    著者: Aditya Bardia, Ingrid A. Mayer, Jennifer R. Diamond, Rebecca Moroose, Steven J. Isakoff, Alexander Starodub, Nikita Shah, Joyce O’Shaughnessy, Kevin Kalinsky, Michael J. Guarino, Vandana G. Abramson, Dejan Juric, Sara M. Tolaney, Jordan Berlin, Wells A. Messersmith, Allyson J. Ocean, William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, David M. Goldenberg, Linda T. Vahdat - Journal of Clinical Oncology 2017 被引用: 409

  9. Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys

    著者: Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, David M. Goldenberg - Clinical Cancer Research 2011 被引用: 300

  10. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

    著者: Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey, Preeti Trisal, Roberto Arrojo, Donglin Liu, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg - Bioconjugate Chemistry 2015 被引用: 296

  11. Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

    著者: Allyson J. Ocean, Alexander Starodub, Aditya Bardia, Linda T. Vahdat, Steven J. Isakoff, Michael J. Guarino, Wells A. Messersmith, Vincent J. Picozzi, Ingrid A. Mayer, William A. Wegener, Pius Maliakal, Serengulam V. Govindan, Robert M. Sharkey, David M. Goldenberg - Cancer 2017 被引用: 236

  12. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    著者: Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Dièras, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky - npj Breast Cancer 2022 被引用: 103

  13. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

    著者: David M. Goldenberg, Robert M. Sharkey - mAbs 2019 被引用: 152

  14. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

    著者: Kevin Kalinsky, Jennifer R. Diamond, Linda T. Vahdat, Sara M. Tolaney, Dejan Juric, Joyce O’Shaughnessy, R Moroose, IA Mayer, Vandana G. Abramson, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, Trishna Goswami, William A. Wegener, Aditya Bardia - Annals of Oncology 2020 被引用: 145

  15. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

    著者: David M. Goldenberg, Robert M. Sharkey - Expert Opinion on Biological Therapy 2020 被引用: 126

  16. A Review of Tissue Substitutes for Ultrasound Imaging

    著者: Martin O. Culjat, David M. Goldenberg, Priyamvada Tewari, Rahul Singh - Ultrasound in Medicine & Biology 2010 被引用: 650

  17. Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

    著者: Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters, W. Thomas Purcell, Alexander Starodub, Leora Horn, Ronald Scheff, Aditya Bardia, Wells A. Messersmith, Jordan Berlin, Allyson J. Ocean, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg, D. Ross Camidge - Journal of Clinical Oncology 2017 被引用: 190

  18. Targeting LGR5 + cells with an antibody-drug conjugate for the treatment of colon cancer

    著者: Melissa R. Junttila, Weiguang Mao, Xi Wang, Bu-Er Wang, Thinh Pham, John A. Flygare, Shang‐Fan Yu, Sharon Yee, David M. Goldenberg, Carter T. Fields, Jeffrey Eastham‐Anderson, Mallika Singh, Rajesh Vij, Jo-Anne Hongo, Ron Firestein, Melissa M. Schutten, Kelly M. Flagella, Paul Polakis, Andrew G. Polson - Science Translational Medicine 2015 被引用: 186

  19. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)

    著者: Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Serengulam V. Govindan, Yang Wang, Edmund A. Rossi, Chien‐Hsing Chang, David M. Goldenberg - Clinical Cancer Research 2015 被引用: 166

  20. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

    著者: Jhanelle E. Gray, Rebecca S. Heist, Alexander Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Charles Schneider, Bryan J. Schneider, Allyson J. Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A. Messersmith, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg - Clinical Cancer Research 2017 被引用: 159

  21. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers

    著者: Rosalyn D. Blumenthal, Emmanuel John De Leon, Hans J. Hansen, David M. Goldenberg - BMC Cancer 2007 被引用: 277

  22. Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy

    著者: Sung-Ju Moon, Serengulam V. Govindan, Thomas M. Cardillo, Christopher D'Souza, Hans J. Hansen, David M. Goldenberg - Journal of Medicinal Chemistry 2008 被引用: 159

  23. Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –wild-type Triple-Negative Breast Cancer

    著者: Thomas M. Cardillo, Robert M. Sharkey, Diane L. Rossi, Roberto Arrojo, Ali Mostafa, David M. Goldenberg - Clinical Cancer Research 2017 被引用: 127

  24. A Novel Method of 18F Radiolabeling for PET

    著者: William J. McBride, Robert M. Sharkey, Habibe Karacay, Christopher D'Souza, Edmund A. Rossi, Peter Laverman, Chien‐Hsing Chang, Otto C. Boerman, David M. Goldenberg - Journal of Nuclear Medicine 2009 被引用: 408